3Paulussen M, Frohlich B, Jurgens H. Ewing tumour: incidence, prognosis and treatment options. Paediatr Drugs, 2001, 3: 899-913.
4Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: De vvita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology 1988. Philadelphia: J B Lippin-cott, 1988.121-142.
5Uchida A, Myoui A, Araki N, et al. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997, 79: 411-415.
7Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing′s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The memorial sloan-kettering experience and a literature review. J Clin Oncol, 2001, 19: 870-880.
8Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest, 2001, 19: 292-315.
9Picci P, Bacci G, Ferrari S, et al. Local recurrence after limb salvage procedures for osteosarcoma: correlation with margins and chemotherapy induced necrosis. J Bone Joint Surg, 1993, 57(Suppl 2): 211-215.
10Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb: amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg, 2002, 84: 88-92.
二级参考文献2
1宋献文，中华外科杂志，1984年，22卷，129页
2Joanna Lin,Wai-tong Leung,Stephen K. W. Ho,K. C. Ho,S. M. Kumta,Con Metreweli,Philip J. Johnson. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma[J] 1995,European Journal of Nuclear Medicine(6):553～555
